The Annals
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 14 June 2005, www.theannals.com, DOI 10.1345/aph.1E350c.
 The Annals of Pharmacotherapy: Vol. 39, No. 7, pp. 1373. DOI 10.1345/aph.1E350c
© 2005 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Correction: sulfonamide cross-reactivity: fact or fiction?

Published Online, June 14, 2005. www.theannals.com, DOI 10.1345/aph.1E350c
In Figure 1 (pg. 291) and throughout the text of "Sulfonamide Cross-Reactivity: Fact or Fiction?",1 the protease inhibitors amprenavir and fosamprenavir should have been classified as sulfonylarylamines.

References

  1. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother 2005;39: 290-301. Epub 2005 Jan 11. DOI 10.1345/aph.1E350[Abstract/Free Full Text]




This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

homecopy help contact us subscription past issues search current issue